Background/Purpose: The rifampicin resistance of Mycobacterium tuberculosis is caused by mutations in the 81-base pair region of the rpoB gene encoding the b-subunit of RNA polymerase. Sequences of the rpoB gene of 68 isolates were analyzed to identify the mutations and to compare the mutations with their related susceptibilities. Methods: Susceptibility tests of 68 M. tuberculosis isolates, collected in Taiwan during the period from 1999 to 2011, were performed by the modified agar proportion method according to Clinical and Laboratory Standards Institute recommendations. Sequences of the rpoB gene and the resistance profiles were analyzed and compared with the data from different geographic regions. Results: Seven alleles were identified. Among 47 isolates of allele 1 (without mutations of rpoB), 46 were rifampicin-susceptible. The other 21 isolates (alleles 2 to 7, with mutations of rpoB) were rifampicin-resistant, including 18 isolates that were multidrug-resistant. Five mutated alleles demonstrated a single mutation. The mutations occurred in the codons 531 (68.2%), 513 (9.1%), 533 (9.1%), 516 (4.5%), and 526 (4.5%). The sensitivity and specificity of rpoB mutations for predicting the rifampicin-resistance of M. tuberculosis were 95.5% and 100%, respectively. Conclusion: The most prevalent mutations of the rpoB gene were missense mutations in the critical codons, encoding Ser-531, Gln-513, Leu-533, Asp-516, and His-526. These mutations had high sensitivity and specificity for predicting the rifampicin-resistance of M. tuberculosis isolates. The resistance profiles and the frequencies of mutated codons of the rpoB gene varied in different geographic regions, indicating that resistance evolved under the selective pressure of the therapeutic regimens and the spread of different genetic clones.
Introduction
Multidrug resistance in Mycobacterium tuberculosis is a global burden. 1 According to a report from World Health Organization, 1 there were an estimated 8.8 million incident cases of tuberculosis (TB) (range, 8.5 millione9.2 million) globally in 2010, 1.1 million deaths (range, 0.9 millione1.2 million) among human immunodeficiency (HIV)-negative cases of TB, and an additional 0.35 million deaths (range, 0.32 millione0.39 million) among people who were HIVpositive. There were an estimated 12.0 million prevalent cases (range, 11.0 millione14.0 million) of TB in 2010. In 2010, there were an estimated 650,000 cases of multidrugresistant TB (MDR-TB) among the world's 12.0 million prevalent cases of TB. Among the estimated 8.8 million new and recurrent cases of TB in 2010, 5.7 million were diagnosed and reported to national TB control programs; among notified cases, there were an estimated 290,000 cases of MDR-TB, of which only 53,000 patients (18%) were reported to have been diagnosed with the condition and enrolled on appropriate treatment. According to the Taiwan Tuberculosis Control Report 2011, 2 the annual incident cases of TB were 13,237 (57.2 per 100,000 population) in 2010, and the estimated rates of MDR-TB among new cases and previously treated cases were 1.1% and 8.2% in 2009, respectively. From a study conducted by a northern Taiwanese medical center during the period from 2003 to 2004, the estimated primary resistance patterns for 486 patients were 5.4% for isoniazid, 0.4% for rifampicin, 0.4% for ethambutol, 0.8% for streptomycin, and 8.0% for pyrazinamide). 3 The resistance of the M. tuberculosis complex to rifampicin is caused by mutations in the 81 base pair (bp) region of the rpoB gene encoding the b-subunit of RNA polymerase. 4e6 The frequency of codon mutations of rpoB in rifampicinresistant M. tuberculosis isolates varied in different geographic regions. The sequence analysis of rpoB of 37 isolates from Italy demonstrated mutations in codons 531 (59.4%), 526 (35.1%), and 516 (8.1%). 7 The data of 86 isolates from China showed mutations in codons 531 (41.0%), 526 (40.0%), 516 (4.0%), 513 (2.0%), and 533 (2.0%). 8 The analysis of prevalence of rpoB mutations was conducted by two reports in Taiwan in the past decade. 9, 10 Further surveillance is clearly needed to detect the evolution of mutations and associated resistance.
In this study, M. tuberculosis isolates, including rifampicin-resistant and rifampicin-susceptible isolates collected in Taiwan during the period from 1990 to 2011, were tested for susceptibility to rifampicin by the modified agar proportion method according to the Clinical and Laboratory Standards Institute (CLSI) recommendations. 11 Sequences of their rpoB genes and resistance profiles were analyzed and compared with the mutations among different geographic regions.
Materials and methods

Collection of M. tuberculosis isolates
Sixty-eight M. tuberculosis isolates were collected for this study, including 39 isolates from Taichung Veterans General Hospital (TCVGH), a medical center in central Taiwan; 25 isolates from 8 hospitals in northern Taiwan and 4 isolates from 1 hospital in southern Taiwan during the period from 1999 to 2011. The sources of specimens included sputum (60, 88.2%), cerebrospinal fluid (5, 7.4%), pleural effusion (2, 2.9%) and abscess (1, 1.5%).
Susceptibility test
The antimycobacterial susceptibility tests were performed according to the CLSI M24-A2 modified agar proportion method. 11 The procedure is performed by inoculating equal quantities of 100Â and 10,000Â dilutions of a standardized inoculum (0.5w1 McFarland) onto 7H10 agar medium (Bio Star, Taichung, Taiwan) with and without the test drug and then incubating them at 35 C, 10% CO 2 for 21 days. The number of colony-forming units growing on the drugcontaining medium compared with those growing on the drug-free medium are then determined and expressed as a percentage. Resistance is defined as growth on drugcontaining agar is greater than 1% of the number of colonies that grow on the drug-free agar. The concentrations of antituberculosis drugs were as follows: isoniazid 0.2 mg/mL, streptomycin 2.0 mg/mL, rifampicin 1.0 mg/mL, and ethambutol 5.0 mg/mL. Multidrug resistance was defined as isolates resistant to at least isoniazid and rifampicin. 11 
DNA sequencing
The DNA was extracted by 10 mg/mL of proteinase K and 5% Tween 20 in 200 mM TRIS-HCl solution (pH 8.3) at 60 C overnight. The polymerase chain reaction (PCR) was performed in a GeneAmp PCR System 9600 (Perkin-Elmer, Norwalk, CT) using the primer pair 5'-TCGAATATCTGG TCCGCTTG -3'；3'-ACACGATCTCGTCGCTAAC-5'. The PCR began with an initial 4-minute denaturation at 94 C, followed by 35 cycles of denaturation at 95 C for 1 minute, annealing at 55 C for 2 minute, and extension at 72 C for 2 minute, and finally an extension step at 72 C for 5 minute. The sequence reactions were performed by adding fluorescent terminators (Perkin-Elmer Applied Biosystems, Foster City, CA) and the primers used in the initial PCR. The sequences were determined with an ABI PRISM 310 and 3100 automated DNA sequencer (Perkin-Elmer Applied Biosystems, Foster City, CA).
The sequences obtained from all 68 isolates were compared and each different sequence was assigned a unique allele number.
Results
The mutations of the rpoB gene and the resistance profiles are listed in Table 1 . Seven alleles were identified. The GenBank sequence database accession numbers of the seven alleles were AY155355 to AY155361. Allele 1 represented the original sequence without mutation, and alleles 2 to 7 demonstrated mutated sequences. Forty-seven isolates were assigned as allele 1, including 27 isolates susceptible to isoniazid, rifampicin, ethambutol, and streptomycin; one isolate resistant to rifampicin and streptomycin; and 19 isolates with other resistance profiles. Five mutated alleles (alleles 2, 4, 5, 6, 7) possessed a single mutation in the 81-bp hot region. The mutations occurred in codons 531 (63.6%, TCG/TTG; 4.5%, TCG/TGG), 513 (9.1%, CAA/AAA), 533 (9.1%, CTG/CCG), 516 (4.5%, GAC/GTC), and 526 (4.5%, CAC/TGC). Among the 21 isolates of alleles 2 to 7, 18 isolates were multidrugresistant; two isolates of allele 2 and one isolate of allele 6 were resistant to rifampicin only. The sensitivity and specificity of rpoB mutations for predicting the rifampicinresistance of the M. tuberculosis complex were 95.5% and 100%, respectively.
The comparison of the frequency of codon mutations in rifampicin-resistant isolates from different geographic regions is listed in Table 2 . The frequency of mutations, e.g., codons 531 (41.0%-63.6%), 513 (0%-6.0%), 533 (0%-7.5%), 526 (10.5%-40.0 %), and 516 (4.0%-16.7%) varied in different geographic regions.
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Discussion
In this study, no novel mutation was detected beyond the 23 mutations described in previous studies. 10, 14 The most common mutations were missense mutations at codons 531 (Ser/Leu; Ser/Try), 513 (Gln/Lys), 533 (Leu/Pro), 516 (Asp/Val), and 526 (His/Cys). This finding is comparable to the results of previous studies for isolates from the United States, 15 10 The most common mutations of 53 (84.1%) of 63 rifampicin-resistant M. tuberculosis isolates, from Kaoshiung (located in southern Taiwan) during the period from 1996 to 1998 were at codons 531 (41.5%), 526 (18.9%), 516 (15.1%), and 533 (7.5%). 9 In this study, codon 531 accounted for 68.2% of mutations, higher than previously reported results in the world. It could be due to the spread of a prevalent clone or sampling bias due to a small number of isolates. The limited mutations for the isolates collected over a long period of time in different geographic regions and the high sensitivity and specificity of the rpoB gene mutation for predicting rifampicin-resistance, indicate that molecular diagnostic techniques (such as the microarray, 17e19 and the Xpert MTB/RIF test 20e22 ) are powerful and reliable methods for detection of rifampicin-resistant or multidrug-resistant isolates.
Mutations at different codons of rpoB could be associated with different levels of rifampicin resistance. The mutation at codon 531 or 526 was associated with high-level resistance to rifampicin (minimum inhibitory concentration [MIC] > 64 mg/mL) 14, 23, 24 and high-level cross-resistance to all rifamycins, whereas mutation at codon 516 was associated with medium-level resistance to rifampicin (MIC Z 32 mg/mL), but susceptibility to rifabutin. 14 However, some isolates with mutation at codon 516 or 533 in India were shown to have high-level resistance to rifampicin (MIC > 128 mg/mL). 13 Although the MIC tests were not performed in this study, multidrug resistance appeared to be prevalent in all the mutated alleles in this study. 11, 23 In earlier studies, strains with the same rpoB genotype but from different geographic areas had similar patterns of drug resistance. 14, 23 In contrast, the 14 isolates of allele 2 demonstrated three different resistance profiles in this study. The resistance profiles could evolve by the selective pressure of therapeutic regimens over a period of time in different geographic regions. 12 One isolate of allele 1, without mutation in the 81-bp region, was resistant to rifampicin. Although resistance to rifampicin is mostly mediated by mutations located in the 81-bp region of rpoB, mutations outside this region could be found occasionally to be associated with resistance to rifampin. Examples were mutations at codon 176 (GTC/TTC), 25 codon 381 (GCG/GTG), 26 codon 572 (ATC to TTC), 27, 28 and codon 490 (CAG to CAT). 16, 29 Another possible mechanism of rifampicin resistance could be due to efflux pumps. 30, 31 In conclusion, the most prevalent mutations of the rpoB gene were missense mutations at the critical codons, encoding Ser-531, Gln-513, Leu-533, Asp-516, and His-526. These mutations had high sensitivity and specificity for predicting the rifampicin resistance of M. tuberculosis isolates. The resistance profiles and the frequencies of mutated codons of the rpoB gene, which varied in different geographic regions, indicate that resistance profiles evolved under the selective pressure of the therapeutic regimens and the spread of different genetic clones.
